We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Read MoreHide Full Article
Smith & Nephew SNATS (SNN - Free Report) recently announced the receipt of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System. The system is made to meet the changing needs of primary hip surgery, such as the growing popularity of anterior approach procedures and the growing significance of ambulatory surgery centers.
Additionally, the CATALYSTEM Primary Hip System makes use of the exclusive, patent-pending ACCUBROACH Technology, which offers demonstrated reproducibility between the broach and implant, ensuring stem seating that is reliable and repeatable.
More on the CATALYSTEM System
To provide a precise fit, the CATALYSTEM Primary Hip System was created utilizing global data sets spanning femoral morphologies, building on the legacy of Smith & Nephew's clinically effective stem designs. With reduced distal stem geometry and shorter lengths, the system have a triple-taper stem design with homogeneous proximal loading that works well for anterior approaches but can also be used for other approaches.
The design of CATALYSTEM facilitates accurate fit and fill proximally without distal interference. It is ideally suited for the direct anterior approach. Additionally, the system is delivered in a single modular tray, which helps drive efficiencies in facilitating more shelf space and reducing sterilization costs.
Smith & Nephew's hip business has reached a significant milestone with the CATALYSTEM Primary Hip System, which enhances the company's current hip portfolio with a primary stem that is perfect for advanced anterior procedures, building on the excellent clinical record of POLAR3. The system is engineered for precision, confidence and surgical efficiencies, and the launch of the new stem combined with the company’s proprietary OXINIUM Technology and integration with its robotics platform will help Smith & Nephew continue to enhance patient outcomes in hip surgery.
Industry Prospects
Per a report by Precedence Research, the global hip replacement market size was estimated at $6.32 billion in 2023 and is expected to reach $10.7 billion by 2033 at a growth rate of 5.4%.
An increase in the number of geriatric patients with osteoarthritis and other pain disorders, such as rheumatoid arthritis, is primarily associated with their increased participation in sports and increased risk of injury during play, which can result in fractures or ligament sprains and an increase in the number of patients requiring hospitalization. The market is growing steadily due to improved navigation for performing surgeries and greater robotic automation and networking.
Notable Developments
In June, SNN announced the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services. This launch is likely to provide personalized solutions for surgeons and patients across partial and total knee arthroplasty procedures.
In April, SNN announced an exclusive distribution agreement with NAVBIT, a specialized player in surgical technology. This exclusive partnership, unveiled during the Australian Orthopedics Association COE Meeting in Sydney, marks a significant step in expanding its implant business in Australia.
Price Performance
For year-to-date period, SNN’s shares have gained 1.6% compared with the industry’s rise of 2.3%. The S&P 500 increased 17% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
SNN carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. (ELV - Free Report) , Hologic (HOLX - Free Report) and Universal Health Services (UHS - Free Report)
Elevance Health, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 12.2%. ELV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Elevance Health’s shares have rallied 22.1% compared with the industry’s 5.5% rise in the past year.
Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.
Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew SNATS (SNN - Free Report) recently announced the receipt of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System. The system is made to meet the changing needs of primary hip surgery, such as the growing popularity of anterior approach procedures and the growing significance of ambulatory surgery centers.
Additionally, the CATALYSTEM Primary Hip System makes use of the exclusive, patent-pending ACCUBROACH Technology, which offers demonstrated reproducibility between the broach and implant, ensuring stem seating that is reliable and repeatable.
More on the CATALYSTEM System
To provide a precise fit, the CATALYSTEM Primary Hip System was created utilizing global data sets spanning femoral morphologies, building on the legacy of Smith & Nephew's clinically effective stem designs. With reduced distal stem geometry and shorter lengths, the system have a triple-taper stem design with homogeneous proximal loading that works well for anterior approaches but can also be used for other approaches.
The design of CATALYSTEM facilitates accurate fit and fill proximally without distal interference. It is ideally suited for the direct anterior approach. Additionally, the system is delivered in a single modular tray, which helps drive efficiencies in facilitating more shelf space and reducing sterilization costs.
Smith & Nephew's hip business has reached a significant milestone with the CATALYSTEM Primary Hip System, which enhances the company's current hip portfolio with a primary stem that is perfect for advanced anterior procedures, building on the excellent clinical record of POLAR3. The system is engineered for precision, confidence and surgical efficiencies, and the launch of the new stem combined with the company’s proprietary OXINIUM Technology and integration with its robotics platform will help Smith & Nephew continue to enhance patient outcomes in hip surgery.
Industry Prospects
Per a report by Precedence Research, the global hip replacement market size was estimated at $6.32 billion in 2023 and is expected to reach $10.7 billion by 2033 at a growth rate of 5.4%.
An increase in the number of geriatric patients with osteoarthritis and other pain disorders, such as rheumatoid arthritis, is primarily associated with their increased participation in sports and increased risk of injury during play, which can result in fractures or ligament sprains and an increase in the number of patients requiring hospitalization. The market is growing steadily due to improved navigation for performing surgeries and greater robotic automation and networking.
Notable Developments
In June, SNN announced the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services. This launch is likely to provide personalized solutions for surgeons and patients across partial and total knee arthroplasty procedures.
In April, SNN announced an exclusive distribution agreement with NAVBIT, a specialized player in surgical technology. This exclusive partnership, unveiled during the Australian Orthopedics Association COE Meeting in Sydney, marks a significant step in expanding its implant business in Australia.
Price Performance
For year-to-date period, SNN’s shares have gained 1.6% compared with the industry’s rise of 2.3%. The S&P 500 increased 17% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
SNN carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. (ELV - Free Report) , Hologic (HOLX - Free Report) and Universal Health Services (UHS - Free Report)
Elevance Health, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 12.2%. ELV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Elevance Health’s shares have rallied 22.1% compared with the industry’s 5.5% rise in the past year.
Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.
Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.